“There has been no major change in the incidence of bladder cancer in the United States for 40 years, and for 30 years there has been almost no therapeutic development for localized or advanced disease. However, in the past few years, 5 immune checkpoint inhibitors [ICIs] have been approved for the treatment of bladder cancer,” said Thomas W. Flaig, MD, Professor of Medicine and Associate Dean, University of Colorado School of Medicine. “We now have a lot more latitude for treating patients, and we have support to pursue more aggressive therapy,” he continued.
Disclosures: Dr. Flaig has disclosed that he has received grant/research support from Agensys, Inc.; Aragon; Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; Bavarian Nordic; Bristol-Myers Squibb Company; Dendreon Corporation; Eli Lilly and Company; Exelixis Inc.; Genentech, Inc.; Hoffmann La Roche; Janssen Pharmaceutica Products, LP; Merck & Co., Inc.; Pfizer Inc./Hospira Inc.; Seattle Genetics, Inc.; SOTIO, LLC; and Tokai. He also has equity interest/stock options in Aurora Oncology.
Morales A, Eidinger G, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180–183.
Bellmunt J, de Wit R, Vaughn DJ, et al.. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.